The UPMC Hillman Cancer Center, previously titled the University of Pittsburgh Cancer Institute, is a National Cancer Institute-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, Pennsylvania, United States, adjacent to UPMC Shadyside.

During the past decade, University of Pittsburgh Cancer Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Pittsburgh Cancer Center" #1 sponsor was "Cell Genesys" with 1 trials, followed by "Compugen Ltd" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "Ludwig Institute for Cancer Research" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Pittsburgh Cancer Center" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator and "Cancer Research Institute, NY, USA" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "University of Pittsburgh Cancer Center" are "Colorectal Cancer" (2 trials), "Advanced/Metastatic Tumors" (1 trials), "Carcinoma, Squamous Cell of Head and Neck" (1 trials), "Endometrial Neoplasms" (1 trials) and "Head and Neck Cancer" (1 trials). Many other conditions were trialed in "University of Pittsburgh Cancer Center" in a lesser frequency.

Most popular intervention types in "University of Pittsburgh Cancer Center" are "Drug" (6 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (2 trials), "Carboplatin" (2 trials), "Paclitaxel" (2 trials), "5-Fluorouracil (5-FU)" (1 trials) and "ABT-888" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Pittsburgh Cancer Center" are 7 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Pittsburgh Cancer Center". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of Pittsburgh Cancer Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University of Pittsburgh Cancer Center, 5 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

University of Pittsburgh Cancer Center has several departments that took part in Clinical trials: "UPMC Hillman Cancer Center Investigational Drug Service" - 2 trials